Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cue BiopharmaCUE +3.76%44 EV-to-OCF is -4.93 as of Aug. 13, 2026. GuruFocus rates CUE with a GF Score™ of 44/100. The stock has 3 warning signs investors should review. Among 1,408 Biotechnology companies, Cue Biopharma ranks better than 55.54% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Cue Biopharma's Enterprise Value is $120.50 Mil.
Cue Biopharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-24.46 Mil. Therefore, Cue Biopharma's EV-to-OCF for today is -4.93.
The historical rank and industry rank for Cue Biopharma's EV-to-OCF or its related term are showing as below:
CUE'
s EV-to-OCF Range Over the Past 10 Years
Min: -22.73 Med: -3.03 Max: -0.14
Current: -4.93
During the past 11 years, the highest EV-to-OCF of Cue Biopharma was -0.14. The lowest was -22.73. And the median was -3.03.
CUE's EV-to-OCF is ranked better than 55.54% of 1408
companies
in the Biotechnology industry
Industry Median: -3.53
vs CUE: -4.93
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cue Biopharma's PE Ratio (TTM) for today is calculated as:
Cue Biopharma's share price for today is $31.77.
Cue Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.580.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cue Biopharma EV-to-OCF Related Terms
Cue Biopharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Cue Biopharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cue Biopharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cue Biopharma EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cue Biopharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Cue Biopharma's EV-to-OCF falls into.
Cue Biopharma's current Enterprise Value is $120.50 Mil.
Cue Biopharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cue Biopharma (CUE) has a EV-to-OCF of -4.93 as of Aug. 13, 2026. According to the industry distribution chart, Cue Biopharma ranks #626 out of 1408 companies in the Biotechnology industry, placing it in the top 44.5%.
Is Cue Biopharma's EV-to-OCF too high?
Cue Biopharma's current EV-to-OCF is -4.93. Based on the distribution chart, Cue Biopharma ranks #626 out of 1408 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cue Biopharma has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's EV-to-OCF compare to CNTB and CDXS?
According to the Biotechnology industry distribution chart, Cue Biopharma ranks #626 out of 1408 companies for EV-to-OCF. This puts Cue Biopharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Cue Biopharma's current EV-to-OCF is -4.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Cue Biopharma (CUE) has a current EV-to-OCF of -4.93. The current EV-to-OCF is -4.93. Cue Biopharma's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Cue Biopharma (CUE), the current EV-to-OCF is -4.93 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
44GF Score
Get the complete analysis for CUE
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CUE has been successfully added to your 
